<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04634357</url>
  </required_header>
  <id_info>
    <org_study_id>ETUS20AFPAR123</org_study_id>
    <nct_id>NCT04634357</nct_id>
  </id_info>
  <brief_title>ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma</brief_title>
  <acronym>ARYA-2</acronym>
  <official_title>An Open-Label, Dose Escalation, Phase I/II Clinical Trial of ET140203 T Cells in Pediatric Subjects With Relapsed/Refractory Hepatoblastoma (HB), Hepatocellular Neoplasm-Not Otherwise Specified (HCN-NOS), or Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eureka Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eureka Therapeutics Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the&#xD;
      safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in&#xD;
      pediatric subjects who are AFP-positive/HLA-A2-positive and have relapsed/refractory HB,&#xD;
      HCN-NOS, or HCC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial starts with a dose escalation phase. A traditional dose escalation model (3+3)&#xD;
      design will be used to determine the recommended phase II dose (RP2D). Subjects will then be&#xD;
      treated at the RP2D in the expansion phase of the trial.&#xD;
&#xD;
      Following treatment, tumor response assessments will be performed at Months 1, 3, 6, 9, 12,&#xD;
      18, and 24. At each tumor response assessment visit, imaging will be performed (triphasic CT&#xD;
      Scan) and used for response evaluation. Serum AFP levels will also be measured at each tumor&#xD;
      response assessment visit.&#xD;
&#xD;
      The active assessment phase of the study will continue for 2 years. Subjects will be followed&#xD;
      for 15 years post-treatment for assessment of treatment safety and overall survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rates of adverse events (AEs) after infusion of ET140203 T cells</measure>
    <time_frame>28 days</time_frame>
    <description>Safety of ET140203 T cells as assessed by the number of adverse events (AEs) after infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity rates of adverse events (AEs) after infusion of ET140203 T cells</measure>
    <time_frame>28 days</time_frame>
    <description>Safety of ET140203 T cells as assessed by the severity of adverse events (AEs) after infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rates of dose limiting toxicities (DLTs) after infusion of ET140203 T cells</measure>
    <time_frame>28 days</time_frame>
    <description>Tolerability of ET140203 T cells after infusions assessed by committee review of dose limiting toxicities (DLTs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The recommended phase 2 dose (RP2D) regimen of ET140203 T cell therapy primarily based on DLT</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The RP2D will be determined by the study Dose Escalation Committee (DEC) and primarily based on DLTs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the efficacy of ET140203 T cells in pediatric subjects with relapsed/refractory HB, HCN-NOS, or HCC</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Response rate will be assessed by radiographic scans and assessed according to RECIST criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the pharmacokinetics of ET140203 T cells after infusion.</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Assess the expansion and persistence of ET140203 T cells circulating in blood over time.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Hepatoblastoma</condition>
  <condition>Hepatocellular Carcinoma (HCC)</condition>
  <condition>Liver Neoplasms</condition>
  <condition>Metastatic Liver Cancer</condition>
  <condition>Liver Cancer</condition>
  <condition>HEMNOS</condition>
  <arm_group>
    <arm_group_label>ET140203 T Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ET140203 T Cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ET140203 T Cells</intervention_name>
    <description>Biological/Vaccine: ET140203 autologous T-cell product&#xD;
Autologous T cells transduced with lentivirus encoding an ET140203 expression construct</description>
    <arm_group_label>ET140203 T Cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed HB, HCN-NOS, or HCC with serum AFP &gt;200ng/ml at the time of&#xD;
             screening and following the most recent line of therapy.&#xD;
&#xD;
          2. Disease reoccurrence after remission following initial standard-of-care (SOC)&#xD;
             treatment (i.e. relapse) or failure of response to SOC treatment (i.e. refractory).&#xD;
&#xD;
          3. Age ≥ 1 year and ≤ 21 years.&#xD;
&#xD;
          4. Molecular Human Leukocyte Antigen (HLA) class I allele typing that confirms subject&#xD;
             carries at least one HLA-A2 allele.&#xD;
&#xD;
          5. Life expectancy of &gt; 4 months per Principal Investigator's opinion.&#xD;
&#xD;
          6. Lansky or Karnofsky Performance Scale ≥ 70.&#xD;
&#xD;
          7. For enrollment to the dose-finding cohort, subjects must have at least one (1) lesion&#xD;
             ≥ 5 mm in diameter or two (2) or more lesions ≥ 3 mm in diameter. For the&#xD;
             dose-expansion cohort, subjects must have measurable disease by RECIST v1.1.&#xD;
&#xD;
          8. Child-Pugh score of B7 or better.&#xD;
&#xD;
          9. Adequate organ function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received the following within two (2) weeks of leukapheresis and within two (2) weeks&#xD;
             of conditioning chemotherapy: cytotoxic chemotherapy, radiation, systemic&#xD;
             corticosteroids, other anti-cancer therapies (including immunotherapeutic agents), or&#xD;
             any other immunosuppressive agents (Note: use of inhaled or topical steroids is not&#xD;
             exclusionary).&#xD;
&#xD;
          2. Concurrently receiving other investigational agents, biological, chemical, or&#xD;
             radiation therapies, while participating in the study.&#xD;
&#xD;
          3. Contraindication for receipt of conditioning chemotherapeutic agents including&#xD;
             Fludarabine and Cyclophosphamide.&#xD;
&#xD;
          4. Active autoimmune disease requiring systemic immunosuppressive therapy.&#xD;
&#xD;
          5. Compromised circulation in the main portal vein, hepatic vein, or vena cava due to&#xD;
             partial or complete obstruction which, in the opinion of the Principal Investigator,&#xD;
             would make the subject unsuitable for the study.&#xD;
&#xD;
          6. History of organ transplant.&#xD;
&#xD;
          7. HB, HCN-NOS, or HCC involving greater than 50% of the liver (volumetric).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pei Wang, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Eureka Therapeutics Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen B Cravotto</last_name>
    <phone>510-722 8719</phone>
    <email>karen.cravotto@eurekainc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pei Wang, PhD</last_name>
    <phone>510-654 7045</phone>
    <email>pei.wang@eurekainc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dana-Farber/Boston Children's Cancer and Blood Disorders Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Miles</last_name>
      <phone>617-632-6223</phone>
      <email>ashleyk_miles@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Allison O'Neill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 4, 2020</study_first_submitted>
  <study_first_submitted_qc>November 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2020</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed/Refractory Hepatoblastoma (HB)</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Hepatocellular Neoplasm-Not Otherwise Specified (HCN-NOS)</keyword>
  <keyword>Hepatocellular Carcinoma (HCC)</keyword>
  <keyword>Liver Cancer</keyword>
  <keyword>T-cell therapy</keyword>
  <keyword>Metastatic Liver Cancer</keyword>
  <keyword>Liver neoplasms</keyword>
  <keyword>HEMNOS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Hepatoblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

